AngioDynamics Gains AngioVac Clot Remover In $55 Mil. Vortex Acquisition
This article was originally published in The Gray Sheet
Deal strengthens peripheral vascular product offerings with the addition of 510(k)-cleared blood clot removal system, which AngioDynamics expects will generate $50 million in annual sales in five years.
You may also be interested in...
The high court declined to hear arguments in the dispute between Biolitec and AngioDynamics on Nov. 30, leaving Biolitec responsible for damages and contempt of court penalties that could be as high as $160 million.
Infraredx appoints new CFO. AngioDynamics names former Navilyst Medical exec to senior VP spot. More people briefs.
Deal worth $372 million makes AngioDynamics the clear number-two competitor in the global vascular access market, second only to Bard.